Adiponectin as an important link in the pathogenesis of protein-energy malnutrition in patients receiving treatment with programmed hemodialysis: yes or no?

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. Evaluation of the relationship between the blood serum adiponectin level and protein-energy malnutrition (PEM) indices in patients receiving programmed hemodialysis (HD).

Material and methods. A total of 645 patients receiving programmed HD treatment were examined, including 300 men and 345 women aged 56.8±12.8 years. All patients received programmed HD treatment for 8.4±5.3 years. Nutritional status was assessed to diagnose PEM using the method proposed by ISRNM (International Society of Renal Nutrition and Metabolism). Serum adiponectin levels were determined by a method based on a three-stage "sandwich" version of solid-phase enzyme-linked immunosorbent assay using mono- and polyclonal antibodies to adiponectin using the commercial Adiponectin ELISA kit (Mediagnost, Germany), in accordance with the manufacturer's instructions. Reference values for adiponectin were: for women: 3.58–9.66 ng/ml, for men: 2–5.6 ng/ml.

Results. The mean values of adiponectin levels in patients without signs of PEM were 8.4±3.0 ng/ml, and in patients with PEM – 12.1±2.6 ng/ml (p<0.0001). The results of nonparametric correlation analysis revealed negative statistically significant relationships between the serum adiponectin level and the level of the main indicators of nutritional status: total serum protein (Rs = - 0.472; p < 0.0001), serum albumin (Rs = - 0.764; p < 0.0001), serum prealbumin (Rs = - 0.428, p < 0.0001), serum transferrin (Rs = - 0.577; p < 0.0001), blood lymphocytes (Rs = - 0.518; p < 0.0001), arm muscle circumference - AMC (Rs = - 0.618; p < 0.0001), skeletal muscle mass index, according to bioimpedance analysis (Rs = - 0.636; p < 0.0001)) and positive statistically significant relationships between the serum adiponectin level and the percentage of body fat according to bioimpedancemetry (Rs=0.152; p<0.0001).

Conclusion. The obtained data convincingly demonstrated a close relationship between elevated serum adiponectin levels and PEM in patients receiving treatment with programmed HD.

全文:

受限制的访问

作者简介

Aleksandr Yakovenko

Pavlov First St. Petersburg State Medical University

编辑信件的主要联系方式.
Email: leptin-rulit@mail.ru
ORCID iD: 0000-0003-1045-9336

Cand.Sci. (Med.), Associate Professor at the Department of Nephrology and Dialysis

俄罗斯联邦, St. Petersburg

Yulia Lavrishcheva

Almazov National Medical Research Center

Email: lavrischeva@gmail.com
ORCID iD: 0000-0002-3073-2785

Cand.Sci. (Med.), Associate Professor at the Department of Faculty Therapy with the Clinic

俄罗斯联邦, St. Petersburg

参考

  1. Cheng T.C., Huang S.H., Kao C.L., Hsu P.C. Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications-A Narrative Review. Int. J. Mol. Sci. 2022;23(11):6047. Doi: 10.3390/ ijms23116047.
  2. Thurlow J.S., Joshi M., Yan G. et al. Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am. J. Nephrol. 2021;52(2):98–107. doi: 10.1159/000514550.
  3. Carrero J.J., Thomas F., Nagy K. et al. Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies From the International Society of Renal Nutrition and Metabolism. J. Renal Nutrition. 2018;28(6):380–92. Doi: 10.1053/ j.jrn.2018.08.006.
  4. Kang S.S., Chang J.W., Park Y. Nutritional Status Predicts 10-Year Mortality in Patients with End-Stage Renal Disease on Hemodialysis. Nutrients 2017;9(4):399. doi: 10.3390/nu9040399.
  5. Fouque D., Kalantar-Zadeh K., Kopple J. et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391–8. doi: 10.1038/sj.ki.5002585.
  6. Obi Y., Qader H., Kovesdy C.P., Kalantar-Zadeh K. Latest consensus and update on protein-energy wasting in chronic kidney disease. Curr. Opin. Clin. Nutr. Metab. Care. 2015;18(3):254–62. doi: 10.1097/MCO.0000000000000171.
  7. Gregg L.P., Carmody T., Le D., et al. A Systematic Review and Meta-Analysis of Depression and Protein-Energy Wasting in Kidney Disease. Kidney Int. Rep. 2020;5(3):318–30. doi: 10.1016/j.ekir.2019.12.009.
  8. Markaki А., Psylinakis E., Spyridaki A. Adiponectin and end-stage renal disease. Hormones (Athens) 2016;15(3):345–54. doi: 10.14310/horm.2002.1698.
  9. Harada H., Kai H., Shibata R. et al. New diagnostic index for sarcopenia in patients with cardiovascular diseases. PLoS One. 2017;12(5):e0178123. doi: 10.1371/journal.pone.0178123.
  10. Beberashvili I., Cohen-Cesla T., Khatib A. et al. Comorbidity burden may explain adiponectin’s paradox as a marker of increased mortality risk in hemodialysis patients. Sci. Rep. 2021;11(1):9087. doi: 10.1038/s41598-021-88558-0.
  11. Guebre-Egziabher F., Bernhard J., Funahashi T. et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol. Dial. Transplant. 2005;20(1):129–34. doi: 10.1093/ndt/gfh568.
  12. Coope A., Milanski M., P Araújo E. et al. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus. FEBS Lett. 2008;582(10):1471–6. doi: 10.1016/j.febslet.2008.03.037.

补充文件

附件文件
动作
1. JATS XML
下载